Original Article

Causal effect of beta-blockers on the risk of lung cancer: a Mendelian randomization study

Yi Lu[1,2#], Jiachun Luo[3#], Zhenyu Huo[4#], Fan Ge[5#], Yang Chen[6#], Ying Chen[2#], Qing Zhang[2#], Caichen Li[2], Jinhui Wang[7], Jiayu Gan[8], Ziqiu Cheng[5], Yangbin Li[5], Yi Feng[2], Qiyuan Hu[9], Jianxing He[2,10], Wenhua Liang[2,11]

[1]Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China; [2]Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China; [3]School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China; [4]State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; [5]First Clinical School, Guangzhou Medical University, Guangzhou, China; [6]Mental Health Center, West China Hospital of Sichuan University, Chengdu, China; [7]Second Clinical School, Wenzhou Medical University, Wenzhou, China; [8]Department of Obstetrics and Gynecology, Center for Reproductive Medicine, Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; [9]First Clinical Medical School, the First Hospital, Shanxi Medical University, Taiyuan, China; [10]Department of Thoracic Surgery, Nanfang Hospital of Southern Medical University, Guangzhou, China; [11]Department of Oncology, the First People's Hospital of Zhaoqing, Zhaoqing, China

Contributions: (I) Conception and design: Y Lu, J Luo, Z Huo, F Ge; (II) Administrative support: J He, W Liang, C Li; (III) Provision of study materials or patients: Ying Chen, Q Zhang, C Li, Yang Chen; (IV) Collection and assembly of data: Y Lu, J Luo; (V) Data analysis and interpretation: Y Lu, J Luo, Z Huo, F Ge; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work as co-first authors.

Correspondence to: Jianxing He, MD. Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, No. 28, Qiaozhong Road, Datansha Island, Liwan District, Guangzhou 510120, China; Department of Thoracic Surgery, Nanfang Hospital of Southern Medical University, Guangzhou, China. Email: drjianxing.he@gmail.com; Wenhua Liang, MD. Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, No. 28, Qiaozhong Road, Datansha Island, Liwan District, Guangzhou 510120, China; Department of Oncology, the First People's Hospital of Zhaoqing, Zhaoqing, China. Email: liangwh1987@163.com.

Background: It remains uncertain whether there is a causal association of the use of beta-blockers (BBs) on lung cancer risk. We used a two-sample Mendelian randomization (MR) approach to identify the causal association of BBs and lung cancer risk.

Methods: Twenty-two BB-related single-nucleotide polymorphisms (SNPs) were obtained from the UK Biobank as the instrumental variables (IVs). Genetic summary data information of lung cancer was extracted from the International Lung Cancer Consortium, with a total of 11,348 cases and 15,861 controls. We adopted the inverse-variance weighted (IVW) approach to conduct the MR analyses. Egger-intercept analysis was further performed as sensitivity analysis for pleiotropy evaluation. Additionally, we investigated whether BBs could causally affect the risk of lung cancer through their pharmacological effects.

Results: The current IVW analysis suggested a decreased lung cancer risk in BB users [odds ratio (OR) =0.83; 95% confidence interval (CI): 0.73–0.95; P<0.01]. Results of Egger-intercept analysis demonstrated that no pleiotropy was found (P=0.94), which suggested the robustness of the causality. However, there was little evidence that pharmacological effects mediate the association between BBs and lung cancer.

Conclusions: The current analysis suggested that BBs could decrease the risk of lung cancer but may be not via its pharmacological effects. Further research is in need for elucidating the underlying mechanisms.

Keywords: Mendelian randomization (MR); beta-blockers (BBs); lung cancer; risk factors

Submitted Jul 14, 2023. Accepted for publication Nov 03, 2023. Published online Dec 21, 2023.
doi: 10.21037/jtd-23-1098
View this article at: https://dx.doi.org/10.21037/jtd-23-1098

Introduction

Lung cancer, with an 11.4% of diagnosed incidence and 18.0% of mortality among the total of cancer deaths, was supposed to be the second most commonly diagnosed cancer (1). Although the treatment of lung cancer has been changing with each passing day and emergence of immunotherapy has offered the hope to cure lung cancer permanently, the 5-year survival rate of lung cancer remains low. Hence, the prevention of lung cancer is exceedingly significant, especially to know about the risks and precautions from the aspects of epidemiology and bioinformatics, including cigarette smoking, environmental pollution and pressure (2,3).

Beta-blockers (BBs) are commonly used in the treatment of many cardiovascular diseases (4). It is implicated in recent studies that beta-adrenergic receptor (β-AR) acts as a significant mediator in the growth and/or invasiveness of many malignancies, that is, it could promote tumorigenesis and cancer metastasis (5,6), and enhance suppressive immunity (7); these exciting discoveries of BBs have inspired a new round of research boom. A nested case-control study provided by Saad *et al.* (8) suggested that long-standing use of BBs seems to relate to reduce the risk of pancreatic cancer. Thiele *et al.* (9) proved that non-selective BBs may play a preventive role on cirrhosis patients who would probably suffer from hepatocellular carcinoma in a meta-analysis. However, whether BBs-taken can decrease the risk of lung cancer remains controversial and inconsistent in epidemiological studies.

Mendelian randomization (MR) analysis is not only an epidemiological method to assess the latent pathogenic factors of diseases, but also a novel approach for predicting possibilities of drug repurposing (10,11). MR uses public genetic variants as instrumental variables (IVs) to infer causal effects, with the purpose of eliminating all confounding factors between genetic polymorphism and disease theoretically (12). Moreover, using two-sample MR analysis which is based on the published summary data from large-scale genome-wide association studies (GWASs) can greatly enhance cost efficiency of MR analysis and alleviate the bias of MR caused by overestimation of genetic effect sizes which are induced by GWASs (13,14). This approach has not been used to evaluate the association of BBs and lung cancer, and to verify whether it is caused by the pharmacological effects of BBs including lowering blood pressure, decreasing heart rate, and increasing the level of triglycerides (15-18). In this study, we implemented a two-sample MR analysis to explore the potential causal association between BBs and the risk of lung cancer by using single-nucleotide polymorphisms (SNPs) from large-scale GWAS. We present this article in accordance with the STROBE-MR reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-1098/rc).

Highlight box

Key findings

- This study suggested a decreased lung cancer risk in beta-blocker users (odds ratio =0.83; 95% confidence interval: 0.73–0.95; P<0.01) using Mendelian randomization study. No pleiotropy was found (P=0.94) according to Egger-intercept analysis.

What is known and what is new?

- Observational studies have found that the use of beta-blockers (BBs) affects the risk of developing multiple types of cancer. Many previous studies have suggested that β-adrenergic signaling is associated with lung cancer.
- The causal relationship between the use of BBs and the risk of developing lung cancer is not clear.

What is the implication, and what should change now?

- The intake of BBs may potentially serve as a preventive medication to assist clinical professionals in treating patients with lung cancer.

Methods

Genetic variant selection

We used summary statistics from a GWAS of the UK Biobank on the basis of self-reported medication-use data of 23 medication categories among approximately 320,000 European individuals (19). Threshold of $P<5\times10^{-8}$ was set to be genome-wide significant for SNPs selection. To control

Table 1 Details of studies included in MR study

Trait	First author	Consortium	Study participants	Year	PubMed ID	Website
A unit increase dose of BB	Wu Y	UK Biobank	224,024	2019	31015401	https://www.ukbiobank.ac.uk/
Lung cancer	Wang Y	ILCCO	27,209	2014	24880342	ilcco.iarc.fr
SBP	Warren HR	ICBP-1000G	152,249	2017	28135244	http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=157020
DBP	Warren HR	ICBP-1000G	152,249	2017	28135244	http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=157020
Heart rate	den Hoed M	Global BPgen	174,610	2013	23583979	NA
Triglycerides	Kathiresan S	DGI-GWAS	18,554	2008	18193044	http://www.broad.mit.edu/diabetes
Cigarettes smoked per day	Liu M	GSCAN	341,427	2019	30643251	https://genome.psych.umn.edu/index.php/GSCAN
Alcoholic drinks per week	Liu M	GSCAN	341,427	2019	30643251	https://genome.psych.umn.edu/index.php/GSCAN
BMI	Yengo L	GIANT	681,275	2018	30124842	https://cnsgenomics.com/data.html
Hypertension	Ehret GB	ICBP-GWAS	203,056	2011	21909115	NA
Coronary heart disease*	Schunkert H	UKBCM	86,995	2011	21378990	https://www.ebi.ac.uk/gwas/

*, including myocardial infarction, angina and chromic ischemic heart disease. MR, Mendelian randomization; BB, beta-blocker; ILCCO, International Lung Cancer Consortium; SBP, systolic blood pressure; DBP, diastolic blood pressure; NA, not available; DGI-GWAS, diabetes genetics initiative genome-wide association study; GSCAN, GWAS and Sequencing Consortium of Alcohol and Nicotine use; BMI, body mass index; GIANT, Genetic Investigation of ANthropometric Traits; ICBP-GWAS, International Consortium for Blood Pressure Genome-Wide Association Studies; UKBCM, UK Biobank Cardio Metabolic.

the family-wise error rate (FWER), we further performed an exclusion while mutual linkage disequilibrium (LD) shared larger P value ($P>5\times10^{-8}$) and exceeding limits ($R^2<0.001$) through Bonferroni correction. Besides, we measured F-statistics to evaluate instrument strength. We had 80% power at a 0.05 significance level to detect an odds ratio (OR) of 1.04 according to Brion *et al.* (20), β was detected as 0.09 at a 0.05 significance level with 224,024 samples involved when statistical power reached 80%. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

GWAS summary data on lung cancer

Genetic association estimation from GWAS summary data on lung cancer in our study was collected from the International Lung Cancer Consortium (ILCCO) (European population, 11,348 cases and 15,861 controls) including the histological subtypes of lung adenocarcinomas (LUADs) and lung squamous carcinomas (LUSCs) (*Table 1*) (21). Each of the 22 SNPs associated with BBs was used for assessing the effects on those data of lung cancer for determination of the effect sizes and standard errors.

Statistical analysis

Several MR methods were used to confirm MR estimation of BBs intake for the risk of lung cancer. We combined the Wald ratio for individual SNPs by using inverse-variance weighted (IVW) meta-analysis. The methods of MR-Egger regression and weighted median were used to indirectly test whether the IVs associated with BBs intake would influence lung cancer only by the effect on BBs. Directional pleiotropy was evaluated by the intercept obtained from the Egger regression analysis. We performed Cochran's Q test of the IVW and the MR-Egger estimation to identify if there is heterogeneity among the SNPs. Furthermore, two different histological subtypes including LUAD and LUSC were also conducted for the same analysis. The estimations were presented in the form of OR and 95% confidence

Table 2 MR estimates of the associations between beta-blockers and risk of lung cancer

Outcome	IVW method		MR-Egger		Weighted median method	
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value
Lung cancer	0.8342 (0.7294, 0.9540)	0.0081	0.8210 (0.5206, 1.2947)	0.4062	0.8496 (0.7077, 1.0199)	0.0805
Squamous cell lung cancer	0.7123 (0.5515, 0.9201)	0.0094	0.5334 (0.2299, 1.2378)	0.1590	0.7980 (0.5957, 1.0691)	0.1305
Lung adenocarcinoma	0.8370 (0.6863, 1.0209)	0.0790	1.0872 (0.5596, 2.1125)	0.8076	0.8233 (0.6280, 1.0795)	0.1594

MR, Mendelian randomization; IVW, inverse-variance weighted; OR, odds ratio; CI, confidence interval.

intervals (CIs). P values <0.05 represented statistically significance (22).

The MR methods were following by the three assumptions: (I) the IVs are strongly associated with the use of BBs; (II) the IVs affect lung cancer only through their effects on the use of BBs instead of any causal pathway; (III) the IVs are independent and not affected by any confounding factors (23). A leave-one-out analysis was performed in our study to assess whether a single SNP could determine or bias the MR estimation.

It is noteworthy that no matter how prefect an epidemiological research design is or how exact the measuring instruments are, there will always be the underlying, immeasurable, and overlooked confounders. Smoking (24), alcohol (25), and high body mass index (BMI) (26) are considered as the major causes of lung cancer. Individuals with above features are prone to cardiovascular diseases which require treatment with BBs; the clinical applications of BBs are probably related to lung cancer. Therefore, we considered those mentioned factors as confounding factors between BBs and lung cancer. It allowed us to test the (III) assumption more fully. We conducted MR analysis between BBs and each confounding factors, which allowed us to test the (III) assumption more fully. MR analysis can only provide the effect of lifelong exposure on the outcome (27), and IVs required in our study was chosen from a GWAS study where patients taking lifelong BBs medication based on the literature of Oliver *et al.* (28). Then we evaluated them with similar MR methods. *Table 1* shows the source and details of respective GWAS summary data of those confounding factors.

To explore the potential mechanisms, we used the MR methods defined in the preceding section and identified the type of BBs and their pharmacology action in the DrugBank database (29) and selected the major pharmacological functions: lowering blood pressure; systolic blood pressure (SBP) and diastolic blood pressure (DBP); slowing heart rate; increasing the concentration of triglycerides. Genetic effects on SBP and DBP were obtained from the UK Biobank (30) (equal to the drop of SBP or DBP in every 10 mmHg), while the association with heart rate based on the GWAS data from a meta-analysis of GWASs (31). Genetic instruments for triglycerides (equal to the standard deviation increase of triglycerides) were collected from the diabetes genetics initiative (DGI) study, FUSION study and the SardiNIA study (32). All MR analyses were conducted in R (version 4.0.5; R Foundation for Statistical Computing, Vienna, Austria) (33). All the P values were 2-tailed.

Results

Genetic instruments

As genetic instruments for BBs, we selected 59 loci that related to BBs at the genome-wide significance threshold of $P<5\times10^{-8}$ (detailed information is shown in Table S1). After selection and exclusion, 22 SNPs in total closely associated with BBs were identified as the final IVs, which explained 3.38% of the variation of using BBs across individuals (table available at https://cdn.amegroups.cn/static/public/jtd-23-1098-1.xlsx). The result of F-statistics was 132.79 which meant that the instruments used in our study would powerfully predict (F >100) the IVs used in our analysis (34).

Causal effect on BBs and lung cancer

The process of conducting two-sample MR analysis is indicated in Figure S1. Firstly, the result based on MR analyses (*Table 2*) showed that genetically predicted BBs were statistically associated with a lower risk of lung cancer and had a protective effect on lung cancer. Each additional unit of BBs reduced the risk of suffering lung cancer by

Table 3 Results of sensitivity analyses between beta-blocking agents and lung cancer

Outcome	MR method	Heterogeneity statistics		MR-Egger regression method	
		Cochran Q [Q_df]	P value	Intercept [SE]	P value
Lung cancer	MR-Egger	23.65 [20]	0.2579	0.0011 [0.015]	0.944
	IVW	23.66 [21]	0.3099		
Squamous cell lung cancer	MR-Egger	36.9 [20]	0.0120	0.02 [0.029]	0.487
	IVW	37.82 [21]	0.0135		
Lung adenocarcinoma	MR-Egger	21.19 [20]	0.3859	−0.018 [0.022]	0.428
	IVW	21.89 [21]	0.4061		

MR, Mendelian randomization; df, degrees of freedom; SE, standard error; IVW, inverse-variance weighted.

Table 4 Causal effects between genetically predicted confounders and beta-blockers and lung cancer

Outcomes	Causal effect (95% CI)	P value
Cigarettes smoked per day	1.0006 (0.9969, 1.0043)	0.7496
Alcoholic drinks per week	0.9987 (0.9934, 1.0039)	0.6156
BMI	0.9996 (0.9984, 1.0007)	0.4741
Hypertension	1.0025 (0.9929, 1.0056)	0.1087
Coronary heart disease*	1.0001 (0.9992, 1.0011)	0.7909

*, including myocardial infarction, angina and chromic ischemic heart disease. CI, confidence interval; BMI, body mass index.

17% (OR =0.83; 95% CI: 0.73–0.95; P<0.01). We obtained the similar causal effect from LUSC subgroup (OR =0.71; 95% CI: 0.55–0.92; P<0.01), while in LUAD subgroup we received the contrary result (OR =0.84; 95% CI: 0.69–1.02; P=0.08) (*Table 2*; Table S2).

Verification of three MR-assumptions

Firstly, we selected SNPs at the genome-wide significance threshold of $P<5\times10^{-8}$ which reached the first MR assumption. Secondly, the Egger intercept was close to zero and P value of it was large (β =0.001, P=0.94) (*Table 3*). It meant that if the effect of horizontal pleiotropy seems to be negligible, it will not contradict the second MR assumption. The MR regression slopes are shown in Figure S2A-S2C. There was no evidence found in the existing GWASs that the included BBs-associated SNPs were dramatically associated with any other phenotypes, which met the requirements of the third assumption. Furthermore, the MR analyses suggested that no confounders interfered with the causality on BBs and lung cancer (*Table 4*).

Heterogeneity, asymmetry, and sensitivity analyses

Table 3 suggested that no directional pleiotropy was found in the MR-Egger regression analysis. Besides, based on Cochran's Q-test and funnel plot, no evidence showed the presence of heterogeneity and asymmetry among these SNPs in the causal effect on BBs and lung cancer or LUAD subgroup. However, heterogeneity was found in subgroup analysis of LUSC (*Table 3*). This may be because the meta-analysis on lung cancer was based on data from four different existing lung cancer GWAS of European populations, meaning that the complexity of case-control studies, identification criteria for primary lung cancer and its classification, composition of series samples, and the traits of the participants themselves were most probably connected with heterogeneity. Individual causal effects of the 22 SNPs on lung cancer are illustrated respectively in Table S2; the results of leave-one-out sensitivity analysis were showed in Table S3 and Figure S3A-S3C.

Causal effect of mediators from BBs on lung cancer

To identify whether the pharmacology effects of BBs could mediate the BBs-lung cancer association, we used the similar MR analysis to investigate it. The results were insufficient to show that IVs of 22 BBs-associated SNPs were genome wide significantly associated with any other phenotypes (*Table 5*), which suggested that the pharmacology effects of BBs may not be the mediator for BBs on lung cancer.

Discussion

In this two-sample MR analysis which involved 31,700 cases and 192,324 controls, it was genetically predicted that the use of BBs was found associated with lung cancer overall

Table 5 Causal effects from the pharmacology effects on lung cancer and its subgroups in using the IVW method

Exposures/ outcomes	Lung cancer		Squamous cell lung cancer		Lung adenocarcinoma	
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value
SBP	0.9892 (0.9427, 1.0380)	0.6597	0.9522 (0.8992, 1.0084)	0.0941	0.9927 (0.9132, 1.0790)	0.8626
DBP	1.0225 (0.9778, 1.0692)	0.3297	1.0235 (0.9646, 1.0860)	0.4419	1.0167 (0.9588, 1.0782)	0.5793
Heart rate	1.0044 (0.9688, 1.0413)	0.8124	1.0174 (0.9667, 1.0708)	0.5079	1.0208 (0.9712, 1.0728)	0.4185
Triglycerides	1.0200 (0.7543, 1.3794)	0.8975	1.0662 (0.6966, 1.6321)	0.7678	1.0210 (0.6833, 1.5257)	0.9190

IVW, inverse-variance weighted; OR, odds ratio; CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure.

and LUSCs, but not with LUAD. Given the additional analysis of mediator exploration, the results suggested that BBs may reduce the risk of lung cancer through another alternative mechanisms, rather than they were being used in the treatment of common diseases.

A growing number of studies have explored the β-AR expression patterns and supported that activation of β-adrenergic signaling is associated with lung cancer progression, which can be reversed by BBs. Several studies have revealed β-AR expression in lung cancer by using bioinformatics analysis (35) or experimental techniques (36,37). According to Nilsson *et al.* (38), β-AR related gene expression was positive in 159 non-small cell lung cancer (NSCLC) clinical samples and 116 lung cancer cell lines tested by quantitative real time polymerase chain reaction (qRT-PCR). Activated β-AR was correlated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor resistance via mitogen-activated protein kinases (MAPKs) pathway in EGFR-mutant NSCLC cells. In a study investigating β-AR expression and its prognostic value on 328 primary NSCLC tumors samples, β2-AR expression was significantly associated with tumor vascularization and cell proliferation and was an independent biomarker of worse progression free survival (PFS) in stage I LUAD patients (39). Besides, some clinical studies like the one conducted by Jafri *et al.* (40) showed that the use of BBs may protect against lung cancer, as the use of BBs was observed significantly higher in patients without lung cancers. Moreover, a cohort study raised by Lin *et al.* (41) demonstrated that long-term use of carvedilol, a nonselective β-blocker, was associated with lower risk of lung cancer and it could be a potential agent in lung cancer prevention. Therefore, the use of BBs may be a potential alternative to control the incidence of lung cancer, which is consistent with our findings.

In this study, the effect of BBs in prevention of lung cancer was not found in all histological subtypes, possibly driven by different mechanisms of anticancer effects. Current studies have found that abnormally activated β-AR signaling pathways which were induced by chronic stress or the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) contribute to lung epithelial cell transformation, lung tumourigenesis, and angiogenesis, while BBs can reduce this process (42-44). Data from Min *et al.* found that NNK stimulated malignant transformation of normal human lung epithelial and tumor formation via β-AR-mediated insulin-like growth factor 1 receptor (IGF-1R) phosphorylation. After treated with β-AR antagonists, normal human lung epithelial cell lines showed a significantly suppression in NNK-mediated phenotypic transformation (45). Because duration-related cigarette exposure was more strongly related with LUSC (46,47), our findings in this histological subtype might be supported. As for LUAD, Schuller *et al.* (48) demonstrated that only in LUAD of Clara cell phenotype, a group with non-ciliated small airway epithelial cells features, can BBs block the malignant transformation progression stimulated by β-AR signaling. Smoking or psychological stress leads to the release of catecholamines which bind to β-AR and activate protein kinase A by cyclic adenosine monophosphate (cAMP) accumulation, with vascular endothelial-derived growth factor (VEGF) and arachidonic acid (AA) release downstream, resulting in cancer growth stimulation (49-51). Considering the converse effect of BBs in different histological subtypes, researchers should interpret our findings with caution.

Strengths and limitations

Using two-sample MR analysis to investigate the causal effect is the main strength of our study. It helps in mitigating and addressing certain forms of confounding and reversing

causation in conventional observational studies including environment and lifestyle factors of participants (10). For example, cohort studies face the problems of follow-up loss and the status of participants changed over time, while case-control studies fail to confirm specific susceptibility loci of BBs, determine causality, and eliminate various bias like selection bias. Participants were grouped in our study according to randomly allocated genotype, which mimics the procedure of randomized controlled trial (RCT) and prevents the disadvantages such as complicated research design, long duration, and high cost. Considering our large sample sizes with 224,024 samples, and the close association of IVs (F >100), the causal effect can be estimated with high accuracy under a sufficient power value (100%).

However, like other MR analyses, there are some shortcomings in this study. First, the ethnic consistency is required in MR analysis, so our study only applies to European origin, and other populations remain to be explored. Therefore, our results are regionally limited. Second, given that it is impossible to deal with all the existing confounding factors completely and the pleiotropic nature of genetic variants affecting medication-use, we cannot easily exclude the potential and immeasurable confounding factors and residual pleiotropy. In order to minimize errors as much as possible, several sensitivity analyses were used and potential interference factors were taken into account. Though no evidence of horizontal pleiotropic effects was found, we cannot directly conclude that there were no latent confounding factors. Third, we also faced the fact that MR analysis might generate false-negative findings when testing the effect of drugs. MR analysis estimates the effect of lifelong exposure in most cases while medications generally cannot be as an lifelong exposure in strict terms (52). That means that the null finding in our result may be caused by this default rather than the ineffectiveness of the drug.

Further limitations in our study were caused by the lack of detailed data. Firstly, the summary data of BBs from the UK Biobank lacked reasons, duration, dosage, and the subtypes of BBs-taken, thus we could not identify the associations of SNPs with dosage level by pharmacogenomics analyses. Secondly, it is controversial whether the efficacy of BBs in lung cancer prevention is receptor-dependent. Due to data limitations, we could not have a further discussion on the type, selective or non-selective, of BBs. Thirdly, without detailed data of the instruments, we did not get SNPs of the protein targets of BB drug classes. Though independent SNPs associated with BBs pharmacologic action were used in mechanism investigation, how BBs play a role in lung cancer prevention remains unclear.

Conclusions

Our present MR study provided abundant and preliminary evidence that the use of BBs can decrease the risk of lung cancer. This helps researchers understand an alternative way for lung cancer prevention. However, we found little supportive evidence that the decrease of lung cancer risk was caused by the major pharmacologic effects of BBs with the help of combining SNPs and summary data from different GWAS as IVs. Furthermore, some hypotheses raised in some literature may not be directly verified by MR analysis. Further research is required to obtain a definitive answer to the underlying mechanism.

Acknowledgments

We appreciate all the researchers and consortia for providing the high-grade GWAS resources. All data and material are available from the corresponding consortia.
Funding: This study was supported by the China National Science Foundation (Nos. 82022048 and 81871893), the Key Project of Guangzhou Scientific Research Project (No. 201804020030), High-level university construction project of Guangzhou Medical University (Grant No. 2018118069, 2018111031), National College Student Innovation and Entrepreneurship Training Program (Grant No. 202110570007), and the Cultivation of Guangdong College Students' Scientific and Technological Innovation ("Climbing Program" Special Funds) (Grant No. pdjh2022b0430).

Footnote

Reporting Checklist: The authors have completed the STROBE-MR reporting checklist. Available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-1098/rc

Peer Review File: Available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-1098/prf

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-1098/coif). J.H. serves as the Executive Editor-in-Chief of *Journal of Thoracic Disease*

and W.L. serves as an unpaid editorial board member of *Journal of Thoracic Disease* from December 2022 to January 2025. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49.
2. Adams SJ, Stone E, Baldwin DR, et al. Lung cancer screening. Lancet 2023;401:390-408.
3. Thai AA, Solomon BJ, Sequist LV, et al. Lung cancer. Lancet 2021;398:535-54.
4. Arnold SV. Beta-Blockers: The Constantly Swinging Pendulum. J Am Coll Cardiol 2023;81:2312-4.
5. Mravec B, Horvathova L, Hunakova L. Neurobiology of Cancer: the Role of β-Adrenergic Receptor Signaling in Various Tumor Environments. Int J Mol Sci 2020;21:7958.
6. Zahalka AH, Arnal-Estapé A, Maryanovich M, et al. Adrenergic nerves activate an angio-metabolic switch in prostate cancer. Science 2017;358:321-6.
7. Mohammadpour H, MacDonald CR, Qiao G, et al. β2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells. J Clin Invest 2019;129:5537-52.
8. Saad A, Goldstein J, Margalit O, et al. Assessing the effects of beta-blockers on pancreatic cancer risk: A nested case-control study. Pharmacoepidemiol Drug Saf 2020;29:599-604.
9. Thiele M, Albillos A, Abazi R, et al. Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials. Liver Int 2015;35:2009-16.
10. Emdin CA, Khera AV, Kathiresan S. Mendelian Randomization. JAMA 2017;318:1925-6.
11. Walker VM, Davey Smith G, Davies NM, et al. Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. Int J Epidemiol 2017;46:2078-89.
12. Boehm FJ, Zhou X. Statistical methods for Mendelian randomization in genome-wide association studies: A review. Comput Struct Biotechnol J 2022;20:2338-51.
13. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 2014;23:R89-98.
14. Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol 2013;178:1177-84.
15. do Vale GT, Ceron CS, Gonzaga NA, et al. Three Generations of β-blockers: History, Class Differences and Clinical Applicability. Curr Hypertens Rev 2019;15:22-31.
16. O'Rourke ST. Antianginal actions of beta-adrenoceptor antagonists. Am J Pharm Educ 2007;71:95.
17. Prichard BN. Risk-benefits of antihypertensive drugs—beta-blockers. Clin Exp Pharmacol Physiol 1988;15:203-13.
18. Vardeny O, Nicholas G, Andrei A, et al. β-AR polymorphisms and glycemic and lipid parameters in hypertensive individuals receiving carvedilol or metoprolol. Am J Hypertens 2012;25:920-6.
19. Wu Y, Byrne EM, Zheng Z, et al. Genome-wide association study of medication-use and associated disease in the UK Biobank. Nat Commun 2019;10:1891.
20. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol 2013;42:1497-501.
21. Wang Y, McKay JD, Rafnar T, et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet 2014;46:736-41.
22. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife 2018;7:e34408.
23. Glymour MM, Tchetgen Tchetgen EJ, Robins JM. Credible Mendelian randomization studies: approaches

for evaluating the instrumental variable assumptions. Am J Epidemiol 2012;175:332-9.
24. Joseph AM, Rothman AJ, Almirall D, et al. Lung Cancer Screening and Smoking Cessation Clinical Trials. SCALE (Smoking Cessation within the Context of Lung Cancer Screening) Collaboration. Am J Respir Crit Care Med 2018;197:172-82.
25. Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol 2006;7:149-56.
26. Yu D, Zheng W, Johansson M, et al. Overall and Central Obesity and Risk of Lung Cancer: A Pooled Analysis. J Natl Cancer Inst 2018;110:831-42.
27. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol 2015;181:251-60.
28. Oliver E, Mayor F Jr, D'Ocon P. Beta-blockers: Historical Perspective and Mechanisms of Action. Rev Esp Cardiol (Engl Ed) 2019;72:853-62.
29. Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 2018;46:D1074-82.
30. Warren HR, Evangelou E, Cabrera CP, et al. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nat Genet 2017;49:403-15.
31. den Hoed M, Eijgelsheim M, Esko T, et al. Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet 2013;45:621-31.
32. Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008;40:189-97.
33. Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of pleiotropy in Mendelian randomization studies. Hum Mol Genet 2018;27:R195-208.
34. Palmer TM, Lawlor DA, Harbord RM, et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res 2012;21:223-42.
35. Wu X, Zang W, Cui S, et al. Bioinformatics analysis of two microarray gene-expression data sets to select lung adenocarcinoma marker genes. Eur Rev Med Pharmacol Sci 2012;16:1582-7.
36. Coelho M, Imperatori A, Chiaravalli AM, et al. Beta1- and Beta2-Adrenoceptors Expression Patterns in Human Non-small Cell Lung Cancer: Relationship with Cancer Histology. J Neuroimmune Pharmacol 2019;14:697-708.
37. Schuller HM, Plummer HK 3rd, Bochsler PN, et al. Co-expression of beta-adrenergic receptors and cyclooxygenase-2 in pulmonary adenocarcinoma. Int J Oncol 2001;19:445-9.
38. Nilsson MB, Sun H, Diao L, et al. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers. Sci Transl Med 2017;9:eaao4307.
39. Yazawa T, Kaira K, Shimizu K, et al. Prognostic significance of β2-adrenergic receptor expression in non-small cell lung cancer. Am J Transl Res 2016;8:5059-70.
40. Jafri SH, Ali F, Mollaeian A, et al. Major Stressful Life Events and Risk of Developing Lung Cancer: A Case-Control Study. Clin Med Insights Oncol 2019;13:1179554919835798.
41. Lin CS, Lin WS, Lin CL, et al. Carvedilol use is associated with reduced cancer risk: A nationwide population-based cohort study. Int J Cardiol 2015;184:9-13.
42. Zhang Y, Zanos P, Jackson IL, et al. Psychological stress enhances tumor growth and diminishes radiation response in preclinical model of lung cancer. Radiother Oncol 2020;146:126-35.
43. Jang HJ, Boo HJ, Lee HJ, et al. Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells. Cancer Res 2016;76:6607-19.
44. Al-Wadei HA, Al-Wadei MH, Masi T, et al. Chronic exposure to estrogen and the tobacco carcinogen NNK cooperatively modulates nicotinic receptors in small airway epithelial cells. Lung Cancer 2010;69:33-9.
45. Min HY, Boo HJ, Lee HJ, et al. Smoking-associated lung cancer prevention by blockade of the beta-adrenergic receptor-mediated insulin-like growth factor receptor activation. Oncotarget 2016;7:70936-47.
46. Wang X, Wang T, Hua J, et al. Histological types of lung cancer attributable to fine particulate, smoking, and genetic susceptibility. Sci Total Environ 2023;858:159890.
47. Tse LA, Mang OW, Yu IT, et al. Cigarette smoking and changing trends of lung cancer incidence by histological subtype among Chinese male population. Lung Cancer 2009;66:22-7.
48. Schuller HM. The impact of smoking and the influence of other factors on lung cancer. Expert Rev Respir Med 2019;13:761-9.
49. Volpi G, Facchinetti F, Moretto N, et al. Cigarette smoke and α,β-unsaturated aldehydes elicit VEGF release through the p38 MAPK pathway in human airway smooth muscle

cells and lung fibroblasts. Br J Pharmacol 2011;163:649-61.
50. Qin WS, Deng YH, Cui FC. Sulforaphane protects against acrolein-induced oxidative stress and inflammatory responses: modulation of Nrf-2 and COX-2 expression. Arch Med Sci 2016;12:871-80.
51. Al-Wadei HA, Plummer HK 3rd, Ullah MF, et al. Social stress promotes and γ-aminobutyric acid inhibits tumor growth in mouse models of non-small cell lung cancer. Cancer Prev Res (Phila) 2012;5:189-96.
52. Holmes MV, Ala-Korpela M, Smith GD. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol 2017;14:577-90.

Cite this article as: Lu Y, Luo J, Huo Z, Ge F, Chen Y, Chen Y, Zhang Q, Li C, Wang J, Gan J, Cheng Z, Li Y, Feng Y, Hu Q, He J, Liang W. Causal effect of beta-blockers on the risk of lung cancer: a Mendelian randomization study. J Thorac Dis 2023;15(12):6651-6660. doi: 10.21037/jtd-23-1098

Table S1 Detailed information of 59 BBs loci

ID	Phenotype_simple	Initial_sample_description	PubMedID	Year	SNP	chr	Region	Gene	effect_allele	other_allele	beta	se	P value
1	beta blocking agents (unit increase)	31,700 European ancestry cases, 192,324 European ancestry controls	31015401	2019	rs11649807	17	17q25.3	RP11-1055B8.3	G	A	−0.04711686	0.008673469	5.00E−08
2	beta blocking agents	31,700 European ancestry cases, 192,325 European ancestry controls	31015401	2019	rs12459368	19	19p13.11	PGPEP1	G	A	−0.050655983	0.009438776	5.00E−08
3	beta blocking agents	31,700 European ancestry cases, 192,326 European ancestry controls	31015401	2019	rs513159	8	8q22.3	NCALD	T	C	−0.053433497	0.00994898	5.00E−08
4	beta blocking agents	31,700 European ancestry cases, 192,327 European ancestry controls	31015401	2019	rs11026578	11	11p14.3	CTD-2140G10.1	T	C	0.09160002	0.016581633	4.00E−08
5	beta blocking agents	31,700 European ancestry cases, 192,328 European ancestry controls	31015401	2019	rs11731886	4	4q32.1	RP11-588K22.2	C	A	−0.0532221	0.009693878	4.00E−08
6	beta blocking agents	31,700 European ancestry cases, 192,329 European ancestry controls	31015401	2019	rs38853	7	7q31.2	MET	G	NA	0.05038606	0.009183673	4.00E−08
7	beta blocking agents	31,700 European ancestry cases, 192,330 European ancestry controls	31015401	2019	rs778124	1	1p32.2	RP1-158P9.1	A	G	0.047101222	0.008673469	3.00E−08
8	beta blocking agents	31,700 European ancestry cases, 192,331 European ancestry controls	31015401	2019	rs1543927	15	15q24.1	CSK	T	C	0.052594505	0.009438776	2.00E−08
9	beta blocking agents	31,700 European ancestry cases, 192,332 European ancestry controls	31015401	2019	rs4515482	7	7q22.3	COG5	C	A	−0.05535786	0.00994898	2.00E−08
10	beta blocking agents	31,700 European ancestry cases, 192,333 European ancestry controls	31015401	2019	rs4923536	11	11p14.1	RP11-22P4.1	G	A	0.046465393	0.008418367	2.00E−08
11	beta blocking agents	31,700 European ancestry cases, 192,334 European ancestry controls	31015401	2019	rs7652333	3	3p13	RYBP	T	C	0.04740127	0.008418367	2.00E−08
12	beta blocking agents	31,700 European ancestry cases, 192,335 European ancestry controls	31015401	2019	rs7770615	6	6q27	RP11-252P19.1	C	T	−0.092071705	0.016326531	2.00E−08
13	beta blocking agents	31,700 European ancestry cases, 192,336 European ancestry controls	31015401	2019	rs7820612	8	8q21.13	RP11-706J10.1	A	NA	−0.050677635	0.008928571	2.00E−08
14	beta blocking agents	31,700 European ancestry cases, 192,337 European ancestry controls	31015401	2019	rs11023910	11	11p15.2	SOX6	T	A	0.057553295	0.00994898	1.00E−08
15	beta blocking agents	31,700 European ancestry cases, 192,338 European ancestry controls	31015401	2019	rs62043959	16	16q23.2	CMIP	C	A	−0.05248066	0.009438776	1.00E−08
16	beta blocking agents	31,700 European ancestry cases, 192,339 European ancestry controls	31015401	2019	rs417743	1	1p13.3	Y_RNA	T	C	0.05060281	0.008928571	8.00E−09
17	beta blocking agents	31,700 European ancestry cases, 192,340 European ancestry controls	31015401	2019	rs4970834	1	1p13.3	CELSR2	T	C	−0.061627656	0.010714286	8.00E−09
18	beta blocking agents	31,700 European ancestry cases, 192,341 European ancestry controls	31015401	2019	rs113537788	18	18q12.3	OR2K2	G	C	0.18015672	0.030612245	7.00E−09
19	beta blocking agents	31,700 European ancestry cases, 192,342 European ancestry controls	31015401	2019	rs12494396	3	3p21.31	CDC25A	G	C	−0.050804816	0.008673469	6.00E−09
20	beta blocking agents	31,700 European ancestry cases, 192,343 European ancestry controls	31015401	2019	rs17042098	4	4q25	RP11-777N19.1	A	G	0.07974993	0.013520408	5.00E−09
21	beta blocking agents	31,700 European ancestry cases, 192,344 European ancestry controls	31015401	2019	rs664485	11	11q22.3	RP11-819C21.1	A	G	−0.062066164	0.010714286	5.00E−09
22	beta blocking agents	31,700 European ancestry cases, 192,345 European ancestry controls	31015401	2019	rs140570886	6	6q25.3	LPA	C	T	0.19912294	0.033163265	3.00E−09
23	beta blocking agents	31,700 European ancestry cases, 192,346 European ancestry controls	31015401	2019	rs185963	7	7q32.2	KLF14	T	NA	0.050627008	0.008418367	2.00E−09
24	beta blocking agents	31,700 European ancestry cases, 192,347 European ancestry controls	31015401	2019	rs6108787	20	20p12.2	C20orf187	G	T	0.0493109	0.008163265	2.00E−09
25	beta blocking agents	31,700 European ancestry cases, 192,348 European ancestry controls	31015401	2019	rs12906962	15	15q26.2	CTD-2576F9.2	C	T	0.054708365	0.008928571	1.00E−09
26	beta blocking agents	31,700 European ancestry cases, 192,349 European ancestry controls	31015401	2019	rs9286351	4	4q28.3	PCDH18	G	NA	0.05106684	0.008163265	1.00E−09
27	beta blocking agents	31,700 European ancestry cases, 192,350 European ancestry controls	31015401	2019	rs11646715	16	16q12.2	FTO	G	A	−0.05062956	0.008418367	8.00E−10
28	beta blocking agents	31,700 European ancestry cases, 192,351 European ancestry controls	31015401	2019	rs2493136	1	1q42.2	RP11-99J16__A.2	T	C	0.051549222	0.008418367	8.00E−10
29	beta blocking agents	31,700 European ancestry cases, 192,352 European ancestry controls	31015401	2019	rs13154066	5	5p13.3	AC026703.1	T	C	−0.052533343	0.008418367	4.00E−10
30	beta blocking agents	31,700 European ancestry cases, 192,353 European ancestry controls	31015401	2019	rs57748895	1	1p13.2	RP4-663N10.1	T	A	0.19561039	0.033163265	4.00E−10
31	beta blocking agents	31,700 European ancestry cases, 192,354 European ancestry controls	31015401	2019	rs55988870	3	3p24.1	SLC4A7	C	NA	−0.053607434	0.008418367	3.00E−10
32	beta blocking agents	31,700 European ancestry cases, 192,355 European ancestry controls	31015401	2019	rs2105092	6	6q23.2	RP4-662A9.2	A	G	−0.057990488	0.009183673	2.00E−10
33	beta blocking agents	31,700 European ancestry cases, 192,356 European ancestry controls	31015401	2019	rs604723	11	11q22.1	ARHGAP42	T	C	−0.06016691	0.009183673	1.00E−10
34	beta blocking agents	31,700 European ancestry cases, 192,357 European ancestry controls	31015401	2019	rs7368883	2	2p21	THADA	A	G	0.055433426	0.008418367	1.00E−10
35	beta blocking agents	31,700 European ancestry cases, 192,358 European ancestry controls	31015401	2019	rs77924615	16	16p12.3	PDILT	A	G	−0.06863889	0.010459184	7.00E−11

Table S1 (*continued*)

https://dx.doi.org/10.21037/jtd-23-1098

Table S1 (*continued*)

ID	Phenotype_simple	Initial_sample_description	PubMedID	Year	SNP	chr	Region	Gene	effect_allele	other_allele	beta	se	P value
36	beta blocking agents	31,700 European ancestry cases, 192,359 European ancestry controls	31015401	2019	rs10776752	1	1p13.2	WNT2B	T	G	0.10393464	0.015816327	6.00E−11
37	beta blocking agents	31,700 European ancestry cases, 192,360 European ancestry controls	31015401	2019	rs35429	12	12q24.21	RP11-25E2.1	G	NA	−0.05539161	0.008418367	6.00E−11
38	beta blocking agents	31,700 European ancestry cases, 192,361 European ancestry controls	31015401	2019	rs7076100	10	10p12.31	CACNB2	A	NA	−0.05556316	0.008418367	5.00E−11
39	beta blocking agents	31,700 European ancestry cases, 192,362 European ancestry controls	31015401	2019	rs17210692	10	10q21.2	C10orf107	A	G	−0.069548264	0.010459184	4.00E−11
40	beta blocking agents	31,700 European ancestry cases, 192,363 European ancestry controls	31015401	2019	rs1275988	2	2p23.3	KCNK3	C	T	0.05663824	0.008418367	3.00E−11
41	beta blocking agents	31,700 European ancestry cases, 192,364 European ancestry controls	31015401	2019	rs3735533	7	7p15.2	HOTTIP	T	C	−0.10431495	0.015561224	3.00E−11
42	beta blocking agents	31,700 European ancestry cases, 192,365 European ancestry controls	31015401	2019	rs17677603	5	5q23.3	FBN2	G	A	0.057320334	0.008418367	2.00E−11
43	beta blocking agents	31,700 European ancestry cases, 192,366 European ancestry controls	31015401	2019	rs258317	16	16q24.3	C16orf55	T	NA	−0.056158982	0.008418367	2.00E−11
44	beta blocking agents	31,700 European ancestry cases, 192,367 European ancestry controls	31015401	2019	rs7442660	5	5q33.3	RP11-542A14.1	A	G	−0.058263786	0.008673469	1.00E−11
45	beta blocking agents	31,700 European ancestry cases, 192,368 European ancestry controls	31015401	2019	rs36047283	19	19p13.2	INSR	G	A	−0.085640155	0.0125	7.00E−12
46	beta blocking agents	31,700 European ancestry cases, 192,369 European ancestry controls	31015401	2019	rs167479	19	19p13.2	RGL3	T	NA	−0.056873344	0.008163265	5.00E−12
47	beta blocking agents	31,700 European ancestry cases, 192,370 European ancestry controls	31015401	2019	rs78302204	20	20q13.32	ZNF831	A	G	0.0956007	0.013520408	1.00E−12
48	beta blocking agents	31,700 European ancestry cases, 192,371 European ancestry controls	31015401	2019	rs74617384	6	6q25.3	LPA	T	NA	0.110204026	0.015306122	4.00E−13
49	beta blocking agents	31,700 European ancestry cases, 192,372 European ancestry controls	31015401	2019	rs12046278	1	1p36.22	CASZ1	C	T	0.063121654	0.008673469	3.00E−13
50	beta blocking agents	31,700 European ancestry cases, 192,373 European ancestry controls	31015401	2019	rs62436821	6	6q22.33	RP11-73O6.4	A	G	0.060421277	0.008418367	3.00E−13
51	beta blocking agents	31,700 European ancestry cases, 192,374 European ancestry controls	31015401	2019	rs2050265	1	1p36.22	CLCN6	G	A	−0.08317471	0.01122449	7.00E−14
52	beta blocking agents	31,700 European ancestry cases, 192,375 European ancestry controls	31015401	2019	rs11066301	12	12q24.13	PTPN11	G	A	0.06485496	0.008163265	7.00E−15
53	beta blocking agents	31,700 European ancestry cases, 192,376 European ancestry controls	31015401	2019	rs1973765	11	11p15.5	LSP1	C	T	0.06669115	0.008418367	5.00E−15
54	beta blocking agents	31,700 European ancestry cases, 192,377 European ancestry controls	31015401	2019	rs6039216	20	20p12.3	PLCB1	C	T	−0.06730723	0.008418367	4.00E−15
55	beta blocking agents	31,700 European ancestry cases, 192,378 European ancestry controls	31015401	2019	rs2891168	9	9p21.3	CDKN2B-AS1	G	A	0.07148465	0.008418367	4.00E−18
56	beta blocking agents	31,700 European ancestry cases, 192,379 European ancestry controls	31015401	2019	rs3918226	7	7q36.1	NOS3	T	C	0.14636576	0.015306122	8.00E−21
57	beta blocking agents	31,700 European ancestry cases, 192,380 European ancestry controls	31015401	2019	rs7183988	15	15q26.1	FES	T	G	0.07811903	0.008163265	4.00E−21
58	beta blocking agents	31,700 European ancestry cases, 192,381 European ancestry controls	31015401	2019	rs7310615	12	12q24.12	SH2B3	C	G	0.07970556	0.008418367	8.00E−22
59	beta blocking agents	31,700 European ancestry cases, 192,382 European ancestry controls	31015401	2019	rs13125101	4	4q21.21	FGF5	A	G	0.097112074	0.009183673	2.00E−26

BBs, beta-blockers; SNP, single nucleotide polymorphism; se, standard error; NA, not available.

https://dx.doi.org/10.21037/jtd-23-1098



Figure S1 Process of conducting two-sample MR analysis in our study. SNP, single-nucleotide polymorphism; BBs, beta-blockers; LD, linkage disequilibrium; MR, Mendelian randomization; BMI, body mass index.

https://dx.doi.org/10.21037/jtd-23-1098

Table S2 Association of each SNP related to BBs and the risk of lung cancer and its subtypes

ID	Exposure	Outcome	id.exposure	id.outcome	Sample size	SNP	beta	se	P value
1	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs10776752	0.877209947	0.524310278	0.09431271
2	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs11023910	1.06335354	0.629242861	0.091048295
3	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs12046278	−0.295087325	0.455390475	0.516993051
4	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs1275988	−1.036469354	0.464068093	0.025519785
5	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs13125101	−0.183822662	0.305914587	0.547909669
6	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs1543927	−0.416648089	0.558081115	0.455321571
7	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs17042098	0.457640527	0.531147802	0.388903959
8	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs17677603	0.341487892	0.507952379	0.501403372
9	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs1973765	−0.254230134	0.444766659	0.567590693
10	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs2493136	−0.183741279	0.527631629	0.7276616
11	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs2891168	−0.431387718	0.374374079	0.249201694
12	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs3918226	−0.108970158	0.355670616	0.759315774
13	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs4923536	−0.410931637	0.581034578	0.479416551
14	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs57748895	−0.131249674	0.525345305	0.802714907
15	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs6108787	−0.076801681	0.550243455	0.888993711
16	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs62436821	−0.83741527	0.434383404	0.053876873
17	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs7183988	−0.465378282	0.348493831	0.18174582
18	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs7368883	0.498080346	0.529626294	0.346993274
19	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs7652333	−0.372479472	0.608021684	0.540134997
20	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs778124	−0.872238516	0.576078472	0.130001314
21	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs78302204	−0.09663674	0.44250722	0.827129502
22	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs9286351	0.343091525	0.560402798	0.540390176
23	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	All—inverse variance weighted	−0.177878014	0.101267427	0.079000075
24	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	All—MR Egger	0.08363088	0.338925363	0.807614396
25	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs10776752	0.390931262	0.322760535	0.225814368
26	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs11023910	0.610635759	0.403382639	0.130079641
27	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs12046278	−0.390602882	0.29503346	0.185527157
28	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs1275988	−0.352050134	0.313110012	0.260857949
29	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs13125101	−0.090332331	0.198492311	0.649042807
30	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs1543927	0.223175406	0.37745388	0.554342633
31	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs17042098	0.202062873	0.342119423	0.554774474
32	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs17677603	−0.564726298	0.315525028	0.073486272
33	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs1973765	−0.436699622	0.288838924	0.130555734
34	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs2493136	−0.01249693	0.347648312	0.971324583
35	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs2891168	−0.585799889	0.241296558	0.015194171
36	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs3918226	−0.438557488	0.226132123	0.052454346

Table S2 (*continued*)

https://dx.doi.org/10.21037/jtd-23-1098

Table S2 (*continued*)

ID	Exposure	Outcome	id.exposure	id.outcome	Sample size	SNP	beta	se	P value
37	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs4923536	−0.281284611	0.380347585	0.459575396
38	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs57748895	−0.07055249	0.35815071	0.84383453
39	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs6108787	0.18334709	0.363104304	0.613598652
40	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs62436821	−0.047568177	0.29605465	0.872350455
41	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs7183988	−0.15638059	0.231608099	0.499551993
42	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs7368883	0.054325706	0.339849101	0.872997319
43	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs7652333	−0.488963692	0.394525294	0.215207682
44	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs778124	−0.77710935	0.377506129	0.039538863
45	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs78302204	−0.288232199	0.27999795	0.303287875
46	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs9286351	0.269100262	0.363817303	0.459507734
47	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	All—inverse variance weighted	−0.181331167	0.068489315	0.008106938
48	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	All—MR Egger	−0.197186511	0.232418258	0.406248522
49	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs10776752	0.267054372	0.481870145	0.579439227
50	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs11023910	0.635244255	0.623856549	0.308557394
51	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs12046278	−0.530507328	0.447453421	0.235774517
52	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs1275988	−0.307977437	0.48262446	0.523388668
53	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs13125101	−0.02546604	0.307201759	0.933933605
54	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs1543927	0.619758661	0.589795455	0.293349212
55	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs17042098	0.089983653	0.516677569	0.861741109
56	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs17677603	−0.820180148	0.478556179	0.086553729
57	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs1973765	−0.181173964	0.452428846	0.688827004
58	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs2493136	−0.125430797	0.530192289	0.812985703
59	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs2891168	−1.596384678	0.344717362	3.64E−06
60	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs3918226	−0.888349844	0.325479128	0.006345731
61	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs4923536	0.235037289	0.596228681	0.693428504
62	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs57748895	−0.351031456	0.508367679	0.489875391
63	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs6108787	0.580981081	0.567075434	0.305588932
64	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs62436821	0.083221346	0.454641169	0.85476003
65	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs7183988	−0.488550613	0.348250612	0.160655371
66	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs7368883	0.422111742	0.528688232	0.42463066
67	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs7652333	−0.90427324	0.590870245	0.125915481
68	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs778124	−1.437915984	0.560792244	0.01034498
69	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs78302204	−0.255809842	0.421639172	0.544047886
70	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs9286351	−0.030807467	0.547047752	0.955090181
71	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	All—inverse variance weighted	−0.339150449	0.130649605	0.009434953
72	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	All—MR Egger	−0.628483423	0.429530721	0.158955754

SNP, single nucleotide polymorphism; BBs, beta-blockers; se, standard error; MR, Mendelian randomization.

https://dx.doi.org/10.21037/jtd-23-1098



Figure S2 Scatter plot of SNP-specific effects. (A) Scatter plot of SNP-specific effects for the associations with BBs and lung cancer. (B) Scatter plot of SNP-specific effects for the associations with BBs and lung adenocarcinoma. (C) Scatter plot of SNP-specific effects for the associations with BBs and squamous cell lung cancer. MR, Mendelian randomization; SNP, single nucleotide polymorphism; BBs, beta-blockers.

https://dx.doi.org/10.21037/jtd-23-1098

Table S3 Leave-one-out sensitivity analysis for lung cancer and its histological subtypes in each BBs

ID	Exposure	Outcome	id.exposure	id.outcome	Sample size	SNP	beta	se	P value
1	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs10776752	−0.2170454	0.10101977	0.031670573
2	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs11023910	−0.2095101	0.10045138	0.037007003
3	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs12046278	−0.1720397	0.10615218	0.105084305
4	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs1275988	−0.136771	0.1015422	0.178000457
5	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs13125101	−0.1771795	0.10969417	0.106264404
6	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs1543927	−0.1700885	0.10499096	0.105225832
7	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs17042098	−0.2008447	0.10198441	0.048911014
8	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs17677603	−0.1984699	0.10314472	0.054330921
9	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs1973765	−0.1738814	0.10637403	0.102128277
10	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs2493136	−0.1776632	0.10565183	0.092648135
11	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs2891168	−0.1587364	0.1063952	0.135712087
12	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs3918226	−0.18369	0.10795525	0.088841977
13	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs4923536	−0.1708815	0.10491488	0.103363118
14	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs57748895	−0.1796019	0.1056493	0.089134328
15	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs6108787	−0.1812733	0.10541258	0.085495201
16	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs62436821	−0.1415924	0.10188754	0.164622236
17	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs7183988	−0.1525311	0.10639872	0.151692031
18	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs7368883	−0.2024518	0.10148184	0.046047716
19	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs7652333	−0.1725569	0.10492421	0.100055291
20	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs778124	−0.1566614	0.10167477	0.123363251
21	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs78302204	−0.1821764	0.10639165	0.08683789
22	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	rs9286351	−0.1947288	0.1032618	0.059324948
23	beta blocking agents (unit increase)	Lung adenocarcinoma || id:ieu-a-965	qvMGUu	ieu-a-965	18336	All	−0.177878	0.10126743	0.079000075
24	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs10776752	−0.2051563	0.06648527	0.002030461
25	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs11023910	−0.2021289	0.06536896	0.001987303
26	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs12046278	−0.1708178	0.0711142	0.016304759
27	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs1275988	−0.173759	0.07124805	0.014736554
28	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs13125101	−0.1920845	0.073842	0.009287387
29	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs1543927	−0.1935089	0.06942543	0.005315078
30	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs17042098	−0.195473	0.06946874	0.004895557
31	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs17677603	−0.1645964	0.06932176	0.017578292
32	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs1973765	−0.1679166	0.07073736	0.017605888
33	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs2493136	−0.1873553	0.07105206	0.008367417
34	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs2891168	−0.1501787	0.06801576	0.02724436
35	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs3918226	−0.1585297	0.07101177	0.025585689

Table S3 (*continued*)

https://dx.doi.org/10.21037/jtd-23-1098

Table S3 (*continued*)

ID	Exposure	Outcome	id.exposure	id.outcome	Sample size	SNP	beta	se	P value
36	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs4923536	−0.178369	0.07110588	0.012124529
37	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs57748895	−0.1850477	0.07119895	0.009348947
38	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs6108787	−0.1932236	0.06972824	0.005586817
39	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs62436821	−0.1880025	0.07158303	0.00863044
40	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs7183988	−0.1834308	0.07305454	0.012043227
41	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs7368883	−0.1901445	0.07072339	0.007175972
42	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs7652333	−0.1728756	0.07019307	0.013783446
43	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs778124	−0.1634004	0.06725582	0.015118213
44	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs78302204	−0.1753352	0.07188696	0.014726311
45	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	rs9286351	−0.1959606	0.06888479	0.004444503
46	beta blocking agents (unit increase)	Lung cancer || id:ieu-a-966	qvMGUu	ieu-a-966	27209	All	−0.1813312	0.06848932	0.008106938
47	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs10776752	−0.3649474	0.13367984	0.006333221
48	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs11023910	−0.3634716	0.13097957	0.005519751
49	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs12046278	−0.3296418	0.13681332	0.015977579
50	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs1275988	−0.3404727	0.13667793	0.012736321
51	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs13125101	−0.3741709	0.13897171	0.007093453
52	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs1543927	−0.366009	0.13077071	0.005128326
53	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs17042098	−0.3549471	0.13502263	0.008568754
54	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs17677603	−0.3183835	0.13481657	0.018196009
55	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs1973765	−0.3468204	0.13685552	0.011270171
56	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs2493136	−0.3466078	0.13588855	0.010751392
57	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs2891168	−0.2301823	0.10969311	0.035867988
58	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs3918226	−0.2851871	0.13437415	0.033809543
59	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs4923536	−0.3548785	0.13397691	0.008077727
60	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs57748895	−0.3386981	0.1363995	0.013023237
61	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs6108787	−0.3670934	0.13092927	0.005051155
62	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs62436821	−0.3594484	0.1354062	0.007940397
63	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs7183988	−0.3264851	0.13906673	0.018890411
64	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs7368883	−0.3658699	0.13228429	0.005678595
65	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs7652333	−0.3233808	0.13403318	0.015835194
66	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs778124	−0.3050074	0.12862998	0.017730422
67	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs78302204	−0.3438438	0.13751889	0.012407472
68	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	rs9286351	−0.3492353	0.13545632	0.009931257
69	beta blocking agents (unit increase)	Squamous cell lung cancer || id:ieu-a-967	qvMGUu	ieu-a-967	18313	All	−0.3391504	0.13064961	0.009434953

BBs, beta-blockers; SNP, single nucleotide polymorphism; se, standard error.

https://dx.doi.org/10.21037/jtd-23-1098



https://dx.doi.org/10.21037/jtd-23-1098



https://dx.doi.org/10.21037/jtd-23-1098



Figure S3 Leave-one-out analysis of SNP-specific effects. (A) Leave-one-out analysis of SNP-specific effects for the associations with BBs and lung cancer. (B) Leave-one-out analysis of SNP-specific effects for the associations with BBs and lung adenocarcinoma. (C) Leave-one-out analysis of SNP-specific effects for the associations with BBs and squamous cell lung cancer. MR, Mendelian randomization; SNP, single nucleotide polymorphism; BBs, beta-blockers.

https://dx.doi.org/10.21037/jtd-23-1098